Neuronetics, Inc. (STIM)

NASDAQ: STIM · IEX Real-Time Price · USD
4.46
-0.01 (-0.22%)
Aug 12, 2022 4:00 PM EDT - Market closed
-0.22%
Market Cap 120.52M
Revenue (ttm) 59.33M
Net Income (ttm) -37.05M
Shares Out 27.02M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 120,343
Open 4.47
Previous Close 4.47
Day's Range 4.38 - 4.52
52-Week Range 1.98 - 8.88
Beta 2.09
Analysts Buy
Price Target 9.86 (+121.1%)
Earnings Date Aug 2, 2022

About STIM

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Jun 28, 2018
Employees 175
Stock Exchange NASDAQ
Ticker Symbol STIM
Full Company Profile

Financial Performance

In 2021, Neuronetics's revenue was $55.31 million, an increase of 12.32% compared to the previous year's $49.24 million. Losses were -$31.19 million, 13.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for STIM stock is "Buy." The 12-month stock price forecast is 9.86, which is an increase of 121.08% from the latest price.

Price Target
$9.86
(121.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Neuronetics (STIM) Just Flashed Golden Cross Signal: Do You Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the ...

Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 9.30% and 6.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics Reports Second Quarter 2022 Financial and Operating Results

MALVERN, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and...

Neuronetics to Present at the Canaccord Genuity 42nd Annual Growth Conference

MALVERN, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the ...

Neuronetics and Alleviant Health Centers Announce Exclusive Partnership

Partnership Will Bring Non-drug NeuroStar® Advanced Therapy for Mental Health to Thousands More Patients

Why Is Neuronetics (STIM) Stock Up 12% Today?

Neuronetics (STIM) stock is taking off on Tuesday after the announcing approval from the FDA for a new use of a metal health treatment. The post Why Is Neuronetics (STIM) Stock Up 12% Today?

Neuronetics gets another FDA clearance for transcranial magnetic stimulation system; shares jump 22%

Shares of Neuronetics Inc. STIM, -6.67% gained 22.5% in premarket trading on Tuesday after the company said it received clearance from the Food and Drug Administration to market its transcranial magneti...

Neuronetics to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call

MALVERN, Pa., July 19, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the ...

Read Why Neuronetics Shares Are Trading Higher Today

The FDA has cleared Neuronetics Inc's (NASDAQ: STIM) NeuroStar Advanced Therapy for Mental Health – to treat anxiety symptoms for adult patients with major depressive disorder (MDD), also known as anxio...

NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression

Indication demonstrates NeuroStar TMS safety and efficacy in improving anxiety symptoms in depressed patients Indication demonstrates NeuroStar TMS safety and efficacy in improving anxiety symptoms in d...

Neuronetics Recognized as Top Non-Invasive Devices Provider in 2022

Technology is awarded for its innovation to treat depression with NeuroStar Advanced Therapy for Mental Health Technology is awarded for its innovation to treat depression with NeuroStar Advanced Therap...

Neuronetics Announces Positive TMS Coverage Policies to Expand Patient Access to NeuroStar TMS Therapy for Mental Health

Proposed Medicare Coverage through First Coast and Novitas MACs Will Reduce Number of Medication Trials for TMS Eligibility Proposed Medicare Coverage through First Coast and Novitas MACs Will Reduce Nu...

Neuronetics to Present at the William Blair 42nd Annual Growth Stock Conference

MALVERN, Pa., May 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the q...

New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Therapy

Published in Brain Stimulation Journal, study describes insights from world's largest depression registry

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 0% and 7.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics Reports First Quarter 2022 Financial and Operating Results

MALVERN, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and ...

Neuronetics and Transformations Care Network Announce Extended Commercial Partnership

MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and ...

Neuronetics TMS Leadership on Display at Clinical TMS Society Annual Meeting

NeuroStar data from largest depression outcomes registry in the world to be highlighted NeuroStar data from largest depression outcomes registry in the world to be highlighted

Neuronetics Files Federal Lawsuit Against Brainsway for Misleading Psychiatrists and Patients

MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the q...

NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder

Clearance allows for more access to non-drug, noninvasive treatment for patients suffering from MDD or OCD Clearance allows for more access to non-drug, noninvasive treatment for patients suffering from...

Executives Buy Around $1M Of 4 Penny Stocks

The ISM services PMI rose to 58.3 in March from 56.5 in the previous month. Investors, meanwhile, focused on some notable insider trades.

Other symbols: EVOLMOVE

Neuronetics Posts Better Than Expected Q4 Results Despite Lower NeuroStar Therapy System Sales

Neuronetics Inc (NASDAQ: STIM) reported Q4 FY21 sales of $15.02 million, down 4% Y/Y, exceeding previously issued guidance of $13.0 million - $14.0 million and the consensus of $14.43 million. U.S. reve...

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 12.12% and 2.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever an...